Journal Article
. 2011 May; 71(13):4617-27.
doi: 10.1158/0008-5472.CAN-11-0422.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

De-Gang Song 1 Qunrui Ye  Carmine Carpenito  Mathilde Poussin  Li-Ping Wang  Chunyan Ji  Mariangela Figini  Carl H June  George Coukos  Daniel J Powell  
  • PMID: 21546571
  •     50 References
  •     127 citations


Human T cells engineered to express a chimeric antigen receptor (CAR) specific for folate receptor-α (FRα) have shown robust antitumor activity against epithelial cancers in vitro but not in the clinic because of their inability to persist and home to tumor in vivo. In this study, CARs were constructed containing a FRα-specific scFv (MOv19) coupled to the T-cell receptor CD3ζ chain signaling module alone (MOv19-ζ) or in combination with the CD137 (4-1BB) costimulatory motif in tandem (MOv19-BBζ). Primary human T cells transduced to express conventional MOv19-ζ or costimulated MOv19-BBζ CARs secreted various proinflammatory cytokines, and exerted cytotoxic function when cocultured with FRα(+) tumor cells in vitro. However, only transfer of human T cells expressing the costimulated MOv19-BBζ CAR mediated tumor regression in immunodeficient mice bearing large, established FRα(+) human cancer. MOv19-BBζ CAR T-cell infusion mediated tumor regression in models of metastatic intraperitoneal, subcutaneous, and lung-involved human ovarian cancer. Importantly, tumor response was associated with the selective survival and tumor localization of human T cells in vivo and was only observed in mice receiving costimulated MOv19-BBζ CAR T cells. T-cell persistence and antitumor activity were primarily antigen-driven; however, antigen-independent CD137 signaling by CAR improved T-cell persistence but not antitumor activity in vivo. Our results show that anti-FRα CAR outfitted with CD137 costimulatory signaling in tandem overcome issues of T-cell persistence and tumor localization that limit the conventional FRα T-cell targeting strategy to provide potent antitumor activity in vivo.

Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.
Christine E Brown, Christine L Wright, +8 authors, Michael C Jensen.
J Immunol Methods, 2005 Mar 22; 297(1-2). PMID: 15777929
Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection.
M Figini, L Obici, +4 authors, S Canevari.
Cancer Res, 1998 Mar 21; 58(5). PMID: 9500461
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
Paul F Robbins, Mark E Dudley, +6 authors, Steven A Rosenberg.
J Immunol, 2004 Dec 09; 173(12). PMID: 15585832    Free PMC article.
Highly Cited.
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kimberly R Kalli, Ann L Oberg, +4 authors, Lynn C Hartmann.
Gynecol Oncol, 2008 Jan 29; 108(3). PMID: 18222534    Free PMC article.
Highly Cited.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Richard A Morgan, James C Yang, +3 authors, Steven A Rosenberg.
Mol Ther, 2010 Feb 25; 18(4). PMID: 20179677    Free PMC article.
Highly Cited.
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
Juhua Zhou, Xinglei Shen, +3 authors, Paul F Robbins.
J Immunol, 2005 Nov 08; 175(10). PMID: 16272366    Free PMC article.
Highly Cited.
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.
S D Weitman, R H Lark, +4 authors, B A Kamen.
Cancer Res, 1992 Jun 25; 52(12). PMID: 1596899
Highly Cited.
Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.
S Miotti, S Canevari, +6 authors, M I Colnaghi.
Int J Cancer, 1987 Mar 15; 39(3). PMID: 2434438
Highly Cited.
Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
B L Levine, W B Bernstein, +4 authors, C H June.
J Immunol, 1998 Apr 29; 159(12). PMID: 9550389
Highly Cited.
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Douglas C Palmer, Sanjeeve Balasubramaniam, +10 authors, Nicholas P Restifo.
J Immunol, 2004 Dec 09; 173(12). PMID: 15585842    Free PMC article.
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Michael H Kershaw, Jennifer A Westwood, +11 authors, Patrick Hwu.
Clin Cancer Res, 2006 Oct 26; 12(20 Pt 1). PMID: 17062687    Free PMC article.
Highly Cited.
Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy.
S Mukai, J Kjaergaard, S Shu, G E Plautz.
Cancer Res, 1999 Oct 28; 59(20). PMID: 10537304
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Yuan, Dag André Nymoen, +5 authors, Ben Davidson.
Hum Pathol, 2009 May 21; 40(10). PMID: 19454358
A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Maria Moeller, Nicole M Haynes, +8 authors, Phillip K Darcy.
Cancer Gene Ther, 2004 Apr 03; 11(5). PMID: 15060573
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal.
C Takahashi, R S Mittler, A T Vella.
J Immunol, 1999 May 05; 162(9). PMID: 10227968
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Mark E Dudley, John R Wunderlich, +16 authors, Steven A Rosenberg.
Science, 2002 Sep 21; 298(5594). PMID: 12242449    Free PMC article.
Highly Cited.
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
C Melani, M Figini, +7 authors, M P Colombo.
Cancer Res, 1998 Sep 29; 58(18). PMID: 9751627
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Michael C Milone, Jonathan D Fish, +11 authors, Carl H June.
Mol Ther, 2009 Apr 23; 17(8). PMID: 19384291    Free PMC article.
Highly Cited.
Folate-binding protein is a marker for ovarian cancer.
I G Campbell, T A Jones, W D Foulkes, J Trowsdale.
Cancer Res, 1991 Oct 01; 51(19). PMID: 1717147
Highly Cited.
Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
Mariangela Figini, Franck Martin, +8 authors, Silvana Canevari.
Cancer Immunol Immunother, 2008 Aug 16; 58(4). PMID: 18704410
Folate receptor-targeted drugs for cancer and inflammatory diseases.
Philip S Low, Asok C Antony.
Adv Drug Deliv Rev, 2004 Apr 20; 56(8). PMID: 15094205
Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
M A King, L Covassin, +13 authors, D L Greiner.
Clin Exp Immunol, 2009 Aug 08; 157(1). PMID: 19659776    Free PMC article.
Highly Cited.
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
G Gross, T Waks, Z Eshhar.
Proc Natl Acad Sci U S A, 1989 Dec 01; 86(24). PMID: 2513569    Free PMC article.
Highly Cited.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G Till, Michael C Jensen, +13 authors, Oliver W Press.
Blood, 2008 May 30; 112(6). PMID: 18509084    Free PMC article.
Highly Cited.
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Carmine Carpenito, Michael C Milone, +11 authors, Carl H June.
Proc Natl Acad Sci U S A, 2009 Feb 13; 106(9). PMID: 19211796    Free PMC article.
Highly Cited.
Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Kyung H Yi, Hovav Nechushtan, +7 authors, Joseph D Rosenblatt.
Cancer Res, 2007 Oct 19; 67(20). PMID: 17942937
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications.
J F Ross, P K Chaudhuri, M Ratnam.
Cancer, 1994 May 01; 73(9). PMID: 7513252
Highly Cited.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Laura A Johnson, Richard A Morgan, +22 authors, Steven A Rosenberg.
Blood, 2009 May 20; 114(3). PMID: 19451549    Free PMC article.
Highly Cited.
Distant metastases in ovarian cancer: association with p53 mutations.
A K Sood, J I Sorosky, +2 authors, R E Buller.
Clin Cancer Res, 1999 Sep 28; 5(9). PMID: 10499623
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Connie Jackaman, Christine S Bundell, +5 authors, Delia J Nelson.
J Immunol, 2003 Nov 11; 171(10). PMID: 14607902
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
Megan M Suhoski, Tatiana N Golovina, +6 authors, Carl H June.
Mol Ther, 2007 Mar 22; 15(5). PMID: 17375070    Free PMC article.
Highly Cited.
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
C Imai, K Mihara, +4 authors, D Campana.
Leukemia, 2004 Feb 13; 18(4). PMID: 14961035
Highly Cited.
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Jianping Huang, Keith W Kerstann, +4 authors, Paul F Robbins.
J Immunol, 2006 Jun 06; 176(12). PMID: 16751420    Free PMC article.
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
Martin A Pulè, Karin C Straathof, +3 authors, Malcolm K Brenner.
Mol Ther, 2005 Jun 28; 12(5). PMID: 15979412
Highly Cited.
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
John A Craddock, An Lu, +4 authors, Aaron E Foster.
J Immunother, 2010 Sep 16; 33(8). PMID: 20842059    Free PMC article.
Highly Cited.
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
W W Shuford, K Klussman, +11 authors, R S Mittler.
J Exp Med, 1997 Jul 07; 186(1). PMID: 9206996    Free PMC article.
Highly Cited.
Molecular cloning of agonistic and antagonistic monoclonal antibodies against human 4-1BB.
U-H Lee, K B Kwack, J-W Park, B S Kwon.
Eur J Immunogenet, 2002 Oct 03; 29(5). PMID: 12358859
Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
L R Coney, A Tomassetti, +4 authors, V R Zurawski.
Cancer Res, 1991 Nov 25; 51(22). PMID: 1840502
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
Daniel J Powell, Mark E Dudley, Paul F Robbins, Steven A Rosenberg.
Blood, 2004 Sep 04; 105(1). PMID: 15345595    Free PMC article.
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
Julie R Park, David L Digiusto, +8 authors, Michael C Jensen.
Mol Ther, 2007 Feb 15; 15(4). PMID: 17299405
Highly Cited.
Folate receptor overexpression is associated with poor outcome in breast cancer.
Lynn C Hartmann, Gary L Keeney, +5 authors, Philip S Low.
Int J Cancer, 2007 May 10; 121(5). PMID: 17487842
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
S Canevari, G Stoter, +7 authors, C H Lamers.
J Natl Cancer Inst, 1995 Oct 04; 87(19). PMID: 7674333
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
Laura A Johnson, Bianca Heemskerk, +5 authors, Steven A Rosenberg.
J Immunol, 2006 Oct 24; 177(9). PMID: 17056587    Free PMC article.
Highly Cited.
Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.
C Berger, M L Huang, +3 authors, H P Kiem.
J Virol, 2001 Jan 03; 75(2). PMID: 11134293    Free PMC article.
Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells.
S Canevari, S Ménard, +4 authors, M I Colnaghi.
Int J Cancer Suppl, 1988 Jan 01; 2. PMID: 3258291
Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue.
Susanne Markert, Silke Lassmann, +5 authors, Annette Hasenburg.
Anticancer Res, 2009 Feb 05; 28(6A). PMID: 19189636
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
James N Kochenderfer, Wyndham H Wilson, +9 authors, Steven A Rosenberg.
Blood, 2010 Jul 30; 116(20). PMID: 20668228    Free PMC article.
Highly Cited.
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Cor H J Lamers, Ralph Willemsen, +7 authors, Jan W Gratama.
Blood, 2010 Oct 05; 117(1). PMID: 20889925
Highly Cited.
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
Paul F Robbins, Yong F Li, +12 authors, Steven A Rosenberg.
J Immunol, 2008 Apr 22; 180(9). PMID: 18424733    Free PMC article.
Highly Cited.
Overexpression of folate binding protein in ovarian cancers.
G Toffoli, C Cernigoi, +3 authors, M Boiocchi.
Int J Cancer, 1997 Apr 22; 74(2). PMID: 9133455
Highly Cited.
Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.
S Verma, L Provencher, R Dent.
Curr Oncol, 2011 Aug 30; 18(4). PMID: 21874117    Free PMC article.
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Evripidis Lanitis, Mathilde Poussin, +4 authors, Daniel J Powell.
Mol Ther, 2011 Dec 01; 20(3). PMID: 22127019    Free PMC article.
Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients.
Juhua Zhou, Prakash Nagarkatti, Yin Zhong, Mitzi Nagarkatti.
Anticancer Res, 2011 Dec 27; 31(12). PMID: 22199267    Free PMC article.
A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.
Katarzyna Urbanska, Evripidis Lanitis, +6 authors, Daniel J Powell.
Cancer Res, 2012 Feb 09; 72(7). PMID: 22315351    Free PMC article.
A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells.
Sepideh Khaleghi, Fatemeh Rahbarizadeh, +2 authors, Philippe Pognonec.
Int J Hematol, 2012 Mar 13; 95(4). PMID: 22407872
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
David F Stroncek, Carolina Berger, +15 authors, Cornelis J M Melief.
J Transl Med, 2012 Mar 17; 10. PMID: 22420641    Free PMC article.
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Richard A Morgan, Laura A Johnson, +10 authors, Steven A Rosenberg.
Hum Gene Ther, 2012 Jul 12; 23(10). PMID: 22780919    Free PMC article.
Highly Cited.
Current translational and clinical practices in hematopoietic cell and gene therapy.
David L Digiusto, Hans-Peter Kiem.
Cytotherapy, 2012 Jul 18; 14(7). PMID: 22799276    Free PMC article.
Genetically engineered T cells for the treatment of cancer.
M Essand, A S I Loskog.
J Intern Med, 2012 Dec 04; 273(2). PMID: 23198862    Free PMC article.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Waleed Haso, Daniel W Lee, +10 authors, Rimas J Orentas.
Blood, 2012 Dec 18; 121(7). PMID: 23243285    Free PMC article.
Highly Cited.
Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
De-Gang Song, Qunrui Ye, +3 authors, Daniel J Powell.
Hum Gene Ther, 2013 Jan 10; 24(3). PMID: 23297870    Free PMC article.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
James N Kochenderfer, Steven A Rosenberg.
Nat Rev Clin Oncol, 2013 Apr 03; 10(5). PMID: 23546520    Free PMC article.
Highly Cited. Review.
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle.
Andreas A Hombach, Hinrich Abken.
Front Immunol, 2013 Jun 14; 4. PMID: 23761793    Free PMC article.
Gene-engineered T cells for cancer therapy.
Michael H Kershaw, Jennifer A Westwood, Phillip K Darcy.
Nat Rev Cancer, 2013 Jul 25; 13(8). PMID: 23880905
Highly Cited. Review.
Impact of T cell selection methods in the success of clinical adoptive immunotherapy.
Natalia Ramírez, Lorea Beloki, +5 authors, Eduardo Olavarría.
Cell Mol Life Sci, 2013 Oct 01; 71(7). PMID: 24077876
Chimeric antigen receptor modified T cell therapy for B cell malignancies.
Cameron J Turtle.
Int J Hematol, 2013 Dec 18; 99(2). PMID: 24338745
Tumor immunology: multidisciplinary science driving basic and clinical advances.
Bridget P Keenan, Elizabeth M Jaffee, Todd D Armstrong.
Cancer Immunol Res, 2014 Jan 11; 1(1). PMID: 24409447    Free PMC article.
Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Evripidis Lanitis, Mathilde Poussin, +4 authors, Daniel J Powell.
Cancer Immunol Res, 2014 Jan 11; 1(1). PMID: 24409448    Free PMC article.
Highly Cited.
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Victoria Hillerdal, Mohanraj Ramachandran, Justyna Leja, Magnus Essand.
BMC Cancer, 2014 Jan 21; 14. PMID: 24438073    Free PMC article.
B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.
Jenessa B Smith, Caitlin Stashwick, Daniel J Powell.
Gynecol Oncol, 2014 Mar 25; 134(1). PMID: 24657487    Free PMC article.
Clinical application of adoptive T cell therapy in solid tumors.
Yi-Wen Zang, Xiao-Dong Gu, Jian-Bin Xiang, Zong-You Chen.
Med Sci Monit, 2014 Jun 11; 20. PMID: 24912947    Free PMC article.
Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Meili Sun, Huan Shi, +3 authors, Yuping Sun.
Breast Cancer Res, 2014 Jun 13; 16(3). PMID: 24919843    Free PMC article.
NK cells in the tumor microenvironment.
Stine K Larsen, Yanhua Gao, Per H Basse.
Crit Rev Oncog, 2014 Jun 19; 19(1-2). PMID: 24941376    Free PMC article.
Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer.
Junying Wang, Xueju Wang.
Mol Biol Rep, 2014 Jun 28; 41(9). PMID: 24969486
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.
Dong-Sup Chung, Hye-Jin Shin, Yong-Kil Hong.
J Immunol Res, 2014 Jul 11; 2014. PMID: 25009822    Free PMC article.
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Andras Heczey, Daofeng Liu, +10 authors, Leonid S Metelitsa.
Blood, 2014 Jul 23; 124(18). PMID: 25049283    Free PMC article.
Highly Cited.
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Nathan Singh, Xiaojun Liu, +5 authors, Yangbing Zhao.
Cancer Immunol Res, 2014 Aug 12; 2(11). PMID: 25104548    Free PMC article.
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
Huan Shi, Meili Sun, Lin Liu, Zhehai Wang.
Mol Cancer, 2014 Sep 23; 13. PMID: 25241075    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.
Stephen P Santoro, Soorin Kim, +5 authors, George Coukos.
Cancer Immunol Res, 2014 Nov 02; 3(1). PMID: 25358763    Free PMC article.
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Katarzyna Urbanska, Rachel C Lynn, +3 authors, Daniel J Powell.
J Transl Med, 2014 Dec 17; 12. PMID: 25496493    Free PMC article.
Natural Killer Cell Functional Activity After 4-1BB Costimulation.
Shadi sadat Navabi, Mehrnoosh Doroudchi, Ahmad Hosseini Tashnizi, Mojtaba Habibagahi.
Inflammation, 2014 Dec 19; 38(3). PMID: 25520217
Past, present and future targets for immunotherapy in ovarian cancer.
Carlton L Schwab, Diana P English, +2 authors, Alessandro D Santin.
Immunotherapy, 2014 Dec 20; 6(12). PMID: 25524384    Free PMC article.
Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
Rachel C Lynn, Mathilde Poussin, +4 authors, Daniel J Powell.
Blood, 2015 Apr 19; 125(22). PMID: 25887778    Free PMC article.
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Mythili Koneru, Roisin O'Cearbhaill, +2 authors, Renier J Brentjens.
J Transl Med, 2015 Apr 19; 13. PMID: 25890361    Free PMC article.
Highly Cited.
Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell.
Cancer Biol Ther, 2015 Apr 22; 16(6). PMID: 25894333    Free PMC article.
Highly Cited. Review.
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Soranobu Ninomiya, Neeharika Narala, +7 authors, Carlos A Ramos.
Blood, 2015 May 06; 125(25). PMID: 25940712    Free PMC article.
Highly Cited.
A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.
De-Gang Song, Qunrui Ye, +3 authors, Daniel J Powell.
Oncotarget, 2015 Jun 24; 6(25). PMID: 26101914    Free PMC article.
T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
Heather VanSeggelen, Joanne A Hammill, +6 authors, Jonathan L Bramson.
Mol Ther, 2015 Jul 01; 23(10). PMID: 26122933    Free PMC article.
The pharmacology of second-generation chimeric antigen receptors.
Sjoukje J C van der Stegen, Mohamad Hamieh, Michel Sadelain.
Nat Rev Drug Discov, 2015 Jul 02; 14(7). PMID: 26129802    Free PMC article.
Highly Cited. Review.
Smart CARs engineered for cancer immunotherapy.
Saul J Priceman, Stephen J Forman, Christine E Brown.
Curr Opin Oncol, 2015 Sep 10; 27(6). PMID: 26352543    Free PMC article.
A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer.
Huan Shi, Jun Guo, Changzheng Li, Zhehai Wang.
Drug Des Devel Ther, 2015 Sep 12; 9. PMID: 26357465    Free PMC article.
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Keith Schutsky, D Gang Song, +5 authors, Daniel J Powell.
Oncotarget, 2015 Sep 12; 6(30). PMID: 26359629    Free PMC article.
Lymphoma Immunotherapy: Current Status.
Roberta Zappasodi, Filippo de Braud, Massimo Di Nicola.
Front Immunol, 2015 Sep 22; 6. PMID: 26388871    Free PMC article.
Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells.
Xianqiang Liu, Meili Sun, +3 authors, Huan Shi.
Onco Targets Ther, 2015 Nov 07; 8. PMID: 26543378    Free PMC article.
CAR T-cell immunotherapy: The path from the by-road to the freeway?
Lynsey M Whilding, John Maher.
Mol Oncol, 2015 Nov 14; 9(10). PMID: 26563646    Free PMC article.
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Daniel T Harris, David M Kranz.
Trends Pharmacol Sci, 2015 Dec 26; 37(3). PMID: 26705086    Free PMC article.
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.
Hanren Dai, Yao Wang, Xuechun Lu, Weidong Han.
J Natl Cancer Inst, 2016 Jan 29; 108(7). PMID: 26819347    Free PMC article.
Highly Cited. Review.
Strategies and developments of immunotherapies in osteosarcoma.
Jia Wan, Xianghong Zhang, Tang Liu, Xiangsheng Zhang.
Oncol Lett, 2016 Feb 03; 11(1). PMID: 26834853    Free PMC article.
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.
R C Lynn, Y Feng, +4 authors, D J Powell.
Leukemia, 2016 Feb 24; 30(6). PMID: 26898190    Free PMC article.
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Agnes Shuk-Yee Lo, Chen Xu, Akikazu Murakami, Wayne A Marasco.
Mol Ther Oncolytics, 2014 Jan 01; 1. PMID: 27119093    Free PMC article.
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.
Albert T Gacerez, Benjamine Arellano, Charles L Sentman.
J Cell Physiol, 2016 May 11; 231(12). PMID: 27163336    Free PMC article.
Targeting folate receptor alpha for cancer treatment.
Anthony Cheung, Heather J Bax, +11 authors, Sophia N Karagiannis.
Oncotarget, 2016 Jun 02; 7(32). PMID: 27248175    Free PMC article.
Highly Cited. Review.
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
M Kazim Panjwani, Jenessa B Smith, +4 authors, Nicola J Mason.
Mol Ther, 2016 Jul 13; 24(9). PMID: 27401141    Free PMC article.
Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
De-Gang Song, Qunrui Ye, +3 authors, Daniel J Powell.
J Hematol Oncol, 2016 Jul 22; 9(1). PMID: 27439908    Free PMC article.
Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
Yun Bai, Shifeng Kan, +5 authors, Hongkui Deng.
Cell Discov, 2015 Jan 01; 1. PMID: 27462436    Free PMC article.
Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach.
Van Morris, Cathy Eng.
J Gastrointest Oncol, 2016 Oct 18; 7(5). PMID: 27747086    Free PMC article.
Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Qiong J Wang, Zhiya Yu, +4 authors, James C Yang.
Clin Cancer Res, 2016 Nov 03; 23(9). PMID: 27803044    Free PMC article.
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Somala Mohammed, Sujita Sukumaran, +7 authors, Juan F Vera.
Mol Ther, 2017 Jan 28; 25(1). PMID: 28129119    Free PMC article.
Highly Cited.
Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Shengnan Yu, Anping Li, +4 authors, Kongming Wu.
J Hematol Oncol, 2017 Mar 31; 10(1). PMID: 28356156    Free PMC article.
Highly Cited. Review.
Emerging therapies for breast cancer.
Xichun Hu, Wei Huang, Minhao Fan.
J Hematol Oncol, 2017 Apr 30; 10(1). PMID: 28454587    Free PMC article.
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
Sara Caratelli, Tommaso Sconocchia, +9 authors, Giuseppe Sconocchia.
Front Immunol, 2017 May 13; 8. PMID: 28496440    Free PMC article.
TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.
Timothy Nj Bullock.
Curr Opin Immunol, 2017 Jul 28; 47. PMID: 28750279    Free PMC article.
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
Mingxue Fan, Minghao Li, +5 authors, Lei Yu.
J Hematol Oncol, 2017 Aug 31; 10(1). PMID: 28851445    Free PMC article.
Highly Cited. Review.
CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
Xinxin Zhu, Han Cai, +2 authors, Jinghe Lang.
Oncotarget, 2017 Oct 04; 8(38). PMID: 28969098    Free PMC article.
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
Rachel S Leibman, Max W Richardson, +14 authors, James L Riley.
PLoS Pathog, 2017 Oct 13; 13(10). PMID: 29023549    Free PMC article.
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Jiayi Yu, Xiaowen Wu, +11 authors, Jun Guo.
J Hematol Oncol, 2018 Jan 05; 11(1). PMID: 29298689    Free PMC article.
Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.
Yali Han, Chuanyong Liu, +9 authors, Meili Sun.
Am J Cancer Res, 2018 Feb 09; 8(1). PMID: 29416924    Free PMC article.
Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Vishal Jindal, Ena Arora, +3 authors, Rashmika Potdar.
Med Oncol, 2018 Apr 14; 35(5). PMID: 29651744
Nature of tumour rejection antigens in ovarian cancer.
Muzamil Y Want, Amit A Lugade, Sebastiano Battaglia, Kunle Odunsi.
Immunology, 2018 May 18; 155(2). PMID: 29772069    Free PMC article.
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
Concetta Quintarelli, Domenico Orlando, +14 authors, Ignazio Caruana.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872565    Free PMC article.
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Ayguen Sahin, Carlos Sanchez, +3 authors, Bob S Carter.
PLoS One, 2018 Jul 06; 13(7). PMID: 29975720    Free PMC article.
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Yali Han, Wei Xie, De-Gang Song, Daniel J Powell.
J Hematol Oncol, 2018 Jul 08; 11(1). PMID: 29980239    Free PMC article.
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Ye Li, David L Hermanson, Branden S Moriarity, Dan S Kaufman.
Cell Stem Cell, 2018 Aug 08; 23(2). PMID: 30082067    Free PMC article.
Highly Cited.
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis.
Anusha Thadi, Marian Khalili, +3 authors, Wilbur B Bowne.
Vaccines (Basel), 2018 Aug 15; 6(3). PMID: 30103457    Free PMC article.
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
Hannah M Knochelmann, Aubrey S Smith, +3 authors, Chrystal M Paulos.
Front Immunol, 2018 Aug 25; 9. PMID: 30140266    Free PMC article.
Highly Cited. Review.
Strategies to Address Chimeric Antigen Receptor Tonic Signaling.
Adam Ajina, John Maher.
Mol Cancer Ther, 2018 Sep 06; 17(9). PMID: 30181329    Free PMC article.
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
Hui Zhou, Yuling Luo, +5 authors, Xuelei Ma.
BMC Cancer, 2018 Sep 28; 18(1). PMID: 30257649    Free PMC article.
Synthetic immunology: T-cell engineering and adoptive immunotherapy.
Wen Si, Cheng Li, Ping Wei.
Synth Syst Biotechnol, 2018 Oct 23; 3(3). PMID: 30345403    Free PMC article.
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
Juan M Zapata, Gema Perez-Chacon, +4 authors, Ignacio Melero.
Front Immunol, 2018 Dec 14; 9. PMID: 30524423    Free PMC article.
DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.
Ruocong Zhao, Lin Cheng, +15 authors, Peng Li.
Oncoimmunology, 2018 Dec 14; 8(1). PMID: 30546945    Free PMC article.
Application Of Adoptive Immunotherapy In Ovarian Cancer.
Siyu Yang, Xiaojiao Yin, Ying Yue, Siqing Wang.
Onco Targets Ther, 2019 Oct 22; 12. PMID: 31632055    Free PMC article.
Genetically engineered T cells for cancer immunotherapy.
Dan Li, Xue Li, +8 authors, Wei Wang.
Signal Transduct Target Ther, 2019 Oct 23; 4. PMID: 31637014    Free PMC article.
Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.
Wenying Yan, Hongmei Hu, Biao Tang.
Onco Targets Ther, 2019 Nov 07; 12. PMID: 31686857    Free PMC article.
CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.
Ido Somekh, Marini Thian, +33 authors, Kaan Boztug.
Blood, 2019 Sep 11; 134(18). PMID: 31501153    Free PMC article.
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
Nadine Norton, Bahaaeldin Youssef, +18 authors, Keith L Knutson.
NPJ Breast Cancer, 2020 Feb 13; 6. PMID: 32047850    Free PMC article.
Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Ryan D Salinas, Joseph S Durgin, Donald M O'Rourke.
CNS Drugs, 2020 Jan 10; 34(2). PMID: 31916100
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
Darya Alizadeh, Robyn A Wong, +11 authors, Christine E Brown.
Cancer Immunol Res, 2019 Mar 21; 7(5). PMID: 30890531    Free PMC article.
Highly Cited.
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Jiang Lv, Ruocong Zhao, +24 authors, Peng Li.
J Hematol Oncol, 2019 Feb 20; 12(1). PMID: 30777106    Free PMC article.
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Stephanie L Goff, Richard A Morgan, +14 authors, Steven A Rosenberg.
J Immunother, 2019 Mar 19; 42(4). PMID: 30882547    Free PMC article.
Highly Cited.
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
Stefan Stoiber, Bruno L Cadilha, +3 authors, Sebastian Kobold.
Cells, 2019 May 22; 8(5). PMID: 31108883    Free PMC article.
Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
Zhiwei Zhang, Duqing Jiang, +10 authors, Qijun Qian.
Cell Death Dis, 2019 Jun 19; 10(7). PMID: 31209210    Free PMC article.
CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo.
Xiaojun Tang, Qi Tang, +4 authors, Zhenqing Feng.
Onco Targets Ther, 2019 Dec 07; 12. PMID: 31807014    Free PMC article.
From single gene analysis to single cell profiling: a new era for precision medicine.
Maria Teresa Di Martino, Stefania Meschini, +6 authors, Michele Caraglia.
J Exp Clin Cancer Res, 2020 Mar 07; 39(1). PMID: 32138788    Free PMC article.
Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Karlo Perica, Kevin J Curran, Renier J Brentjens, Sergio A Giralt.
Biol Blood Marrow Transplant, 2018 Mar 03; 24(6). PMID: 29499327    Free PMC article.
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.
Innocenza Palaia, Federica Tomao, +2 authors, Pierluigi Benedetti Panici.
Onco Targets Ther, 2020 Jul 04; 13. PMID: 32617007    Free PMC article.
CAR-T design: Elements and their synergistic function.
Jayapriya Jayaraman, Michael P Mellody, +5 authors, Weian Zhao.
EBioMedicine, 2020 Aug 03; 58. PMID: 32739874    Free PMC article.
Chemically Programmable and Switchable CAR-T Therapy.
Junpeng Qi, Kohei Tsuji, +4 authors, Haiyong Peng.
Angew Chem Int Ed Engl, 2020 Apr 25; 59(29). PMID: 32329959    Free PMC article.
The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.
Yasmin R Mohseni, Sim L Tung, +3 authors, Giovanna Lombardi.
Front Immunol, 2020 Aug 15; 11. PMID: 32793236    Free PMC article.
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer.
Alejandra Martinez, Jean-Pierre Delord, Maha Ayyoub, Christel Devaud.
Cancers (Basel), 2020 Jul 08; 12(7). PMID: 32630708    Free PMC article.
FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition.
Xiang Zhang, Fei Wang, +9 authors, Jingfeng Liu.
Cancer Manag Res, 2019 Mar 14; 11. PMID: 30863175    Free PMC article.
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.
Robert Weinkove, Philip George, Nathaniel Dasyam, Alexander D McLellan.
Clin Transl Immunology, 2019 May 22; 8(5). PMID: 31110702    Free PMC article.
Highly Cited. Review.
Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis.
Emmanuel Kwateng Drokow, Hafiz Abdul Waqas Ahmed, +4 authors, Kai Sun.
Ther Clin Risk Manag, 2019 Jun 14; 15. PMID: 31190844    Free PMC article.
An Antibody Fab Fragment-based Chimeric Antigen Receptor Could Efficiently Eliminate Human Thyroid Cancer Cells.
Honghong Duan, Huibin Huang, Guangjun Jing.
J Cancer, 2019 Jun 18; 10(8). PMID: 31205546    Free PMC article.
Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma.
Karlo Perica, Lia Palomba, Renier J Brentjens.
Adv Cell Gene Ther, 2018 Nov 01; 1(3). PMID: 33043278    Free PMC article.
Rictor promotes cell migration and actin polymerization through regulating ABLIM1 phosphorylation in Hepatocellular Carcinoma.
Xin Dong, Mei Feng, +8 authors, Ruirui Kong.
Int J Biol Sci, 2020 Oct 17; 16(15). PMID: 33061800    Free PMC article.
Adoptive cell transfer as personalized immunotherapy for human cancer.
Steven A Rosenberg, Nicholas P Restifo.
Science, 2015 Apr 04; 348(6230). PMID: 25838374    Free PMC article.
Highly Cited. Review.
A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor Vβ Families.
Jie Wang, Katarzyna Urbanska, +5 authors, Daniel J Powell Jr.
Vaccines (Basel), 2020 Nov 05; 8(4). PMID: 33142718    Free PMC article.
GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction.
Jatuporn Sujjitjoon, Elias Sayour, +6 authors, Lung-Ji Chang.
Transl Oncol, 2020 Dec 16; 14(2). PMID: 33321428    Free PMC article.
Driving Immune Responses in the Ovarian Tumor Microenvironment.
Franklin Ning, Christopher B Cole, Christina M Annunziata.
Front Oncol, 2021 Feb 02; 10. PMID: 33520713    Free PMC article.
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.
Benjamin I Philipson, Roddy S O'Connor, +3 authors, Michael C Milone.
Sci Signal, 2020 Apr 03; 13(625). PMID: 32234960    Free PMC article.
Exploiting the folate receptor α in oncology.
Mariana Scaranti, Elena Cojocaru, Susana Banerjee, Udai Banerji.
Nat Rev Clin Oncol, 2020 Mar 11; 17(6). PMID: 32152484
Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Katarzyna M Terlikowska, Bożena Dobrzycka, Sławomir J Terlikowski.
Int J Mol Sci, 2021 Apr 04; 22(7). PMID: 33800608    Free PMC article.
Cellular networks controlling T cell persistence in adoptive cell therapy.
Jack D Chan, Junyun Lai, +3 authors, Phillip K Darcy.
Nat Rev Immunol, 2021 Apr 22; 21(12). PMID: 33879873
Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Suraj Pratap, Zhizhuang J Zhao.
Cancer Rep (Hoboken), 2020 Jul 17; 3(2). PMID: 32671999    Free PMC article.
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.
Colby R Maldini, Daniel T Claiborne, +15 authors, Todd M Allen.
Nat Med, 2020 Sep 02; 26(11). PMID: 32868878
CAR-T cells: Early successes in blood cancer and challenges in solid tumors.
Hassan Dana, Ghanbar Mahmoodi Chalbatani, +5 authors, Thomas J Webster.
Acta Pharm Sin B, 2021 Jun 08; 11(5). PMID: 34094824    Free PMC article.
Mathematical Modelling Based on In Vivo Imaging Suggests CD137-Stimulated Cytotoxic T Lymphocytes Exert Superior Tumour Control Due to an Enhanced Antimitotic Effect on Tumour Cells.
Richard J Beck, Bettina Weigelin, Joost B Beltman.
Cancers (Basel), 2021 Jun 03; 13(11). PMID: 34073822    Free PMC article.
Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents.
Chi Hoon Park.
Cancers (Basel), 2021 Jul 03; 13(13). PMID: 34209505    Free PMC article.
Engineering enhanced CAR T-cells for improved cancer therapy.
Michael C Milone, Jie Xu, +4 authors, J Joseph Melenhorst.
Nat Cancer, 2021 Sep 07; 2(8). PMID: 34485921    Free PMC article.
Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Hyeon Joo Yoo, Biyan Nathanael Harapan.
Immunol Res, 2021 Sep 24; 69(6). PMID: 34554405    Free PMC article.
NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44.
Rüdiger Klapdor, Shuo Wang, +6 authors, Axel Schambach.
Biomedicines, 2021 Oct 24; 9(10). PMID: 34680456    Free PMC article.
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
Racheal Louise Johnson, Michele Cummings, +3 authors, Nicolas Michel Orsi.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944851    Free PMC article.
Emerging CAR T Cell Strategies for the Treatment of AML.
Paresh Vishwasrao, Gongbo Li, +2 authors, Susanta K Hui.
Cancers (Basel), 2022 Mar 11; 14(5). PMID: 35267549    Free PMC article.
A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer.
Dan Li, Hejiao English, +4 authors, Mitchell Ho.
Mol Ther Oncolytics, 2022 Mar 24; 24. PMID: 35317524    Free PMC article.
Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI.
Veronica P Dubois, Olivia C Sehl, Paula J Foster, John A Ronald.
Mol Imaging Biol, 2021 Nov 18; 24(2). PMID: 34786668    Free PMC article.
Emerging Strategies in TCR-Engineered T Cells.
Fang Wei, Xiao-Xia Cheng, John Zhao Xue, Shao-An Xue.
Front Immunol, 2022 Apr 19; 13. PMID: 35432319    Free PMC article.